The Day Voters Rejected Data Centers── US midterms, school search, a pharma write-off: who pays for AI
Download the video (MP4, 16 MB)
For years, the story of artificial intelligence has been about how smart the machines can get. Today's news raises a different question. Who pays the bill for all that intelligence in the end?
The giant facilities behind it ask a lot of the towns they land in. The money to build them is borrowed on the credit of even bigger companies. And the firms using these tools have started to worry about their invoices. If you are expanding these tools in pharma, this is not distant politics. What happens to your plans if endless growth is no longer safe to assume?
Today we look through money and trust, not performance.
01The Election and Data Centers
Source Time Magazine ／ 404 Media ／ Bloomberg.com ／ Benzinga
Our first scene is a polling place far away. Did local residents really want these huge computing sites in their own towns?
| Source | Reported fact |
|---|---|
| Time Magazine | Voter anger over AI data centers helped drive Democratic wins |
| 404 Media | Data centers on the ballot in dozens of districts; most rejected |
| Bloomberg.com | AI data center investment at a turning point after election rout |
| Dan Ives | Democratic wins hurt AI revolution's pace; Big Tech must slow spending |
Time: pro-AI acceleration groups failed to turn spending into political wins
In many towns, the answer was no. Local resistance reportedly shaped the outcome itself. Analysts who track the sector expect large firms to ease back. Money from the boosters did not buy support at the ballot box. So residents now have a say in how far the technology spreads. A force from outside the industry has begun to steer it.
Why did residents say no? The reports do not explain in detail. But these sites draw huge amounts of power. Through power bills and land use, they touch daily life directly. In my reading, that is why opposition comes easily. From the town's view, the burden showed up before any benefit.
Drug companies also rely on outside facilities for their computing. If construction slows, renting capacity may cost more. It might not be there when you need it. Plans built on cheap computing lasting forever may need a second look.
Still, where do the builders find the money for all this? Next, we look behind the financing of these sites.
02Funding the Data Centers
Source Unite.AI
A facility this large costs more than one company can carry alone. So what do the lenders rely on when they hand over the money?
One firm builds and owns the site, and a model developer uses it. The developer promises to rent it for years. A much bigger company promised to cover part of those payments. That lets lenders assume the big company will pay in the end. So these sites stand on the credit of a tech giant.
Why go that far? The backer has long been an investor in this developer. If the developer cannot secure computing capacity, that stake suffers too. In my reading, supporting the developer also protects the backer's own money.
For a single site, that guarantee looks enormous to me. And one broken promise could hit everyone in the chain, from the lenders to the owner.
This matters when a drug company picks a vendor. Prices, and how long a service lasts, depend on how its maker raises money. Checking who stands behind a supplier is ordinary due diligence, I think.
After the money, we turn to the people using these tools. How did one provider respond to users who did not want them at all?
03Schools Saying No to AI, and Search
Source https://tech-insider.org/ ／ CNBC ／ The Japan Times
Users should get to choose whether they use these tools. That sounds obvious. In practice, it is not always true.
One major provider decided to keep its tools for children switched off until each school says yes. At first glance, that hands the choice to the school. But saying no also takes away ordinary web lookups. To get them back, the school must accept machine-written digests too. The freedom to refuse exists only on paper. I see this as a vendor's design making the user's decision.
Why did it come to this? Worry is growing among parents and local education leaders. The provider answered by keeping the assistant and lookups tied together. Politicians have pushed back as well, and the company is busy explaining itself.
The same thing can happen at a drug company. An everyday work tool may get an assistant built in after the fact. If switching it off stops the whole tool, the vendor really holds the decision. It pays to spot a choice that only looks like one.
This fight over control is not limited to children. It has also begun where software engineers do their daily work.
04OpenAI Takes On GitHub
Source OpenAI ／ Axios ／ Microsoft
Will the race in coding assistants be won on intelligence alone? Today's moves suggest a different answer.
Acquires Pierre
OpenAI officially announced the acquisition of Pierre Computer Company, bringing its code storage technology into Codex.
Competing with GitHub
Axios and WSJ reported the aim is to challenge Microsoft-owned GitHub, through startup acquisitions.
Persistent agents
In its October 2026 Copilot Studio update, Microsoft added agents that keep running continuously.
One lab bought a small firm with technology for keeping code. The target is the place where programmers park their work every day. Hold that, and the assistant can handle everything from writing code to keeping it, in my reading. Another giant added assistants that never stop running. The contest seems to be shifting from raw performance to where the work lives.
Why does that place matter? Programmers gather where their code lives. Once they are used to the tools there, they rarely move. For a vendor, that place keeps customers for years. The more convenient it gets, the harder it is to leave.
Drug companies keep internal documents and analysis programs somewhere too. Choosing a tool also means choosing who holds that material. Moving it later takes real effort. So when you pick a home for it, check the exit terms as well.
So where are drug companies themselves trying to place these capabilities? The day's news offers a clue.
05Pharma's AI Investments
Source FourWeekMBA ／ Idéal Investisseur
A drug company putting money into this field must choose. Build the capability inside, or borrow it from outside? On this day, both paths surfaced.
| Deal | Amount | Nature of amount |
|---|---|---|
| A drugmaker folds AI subsidiary InstaDeep into the parent | €96M | AI-related write-off; not a new investment |
| Another drugmaker partners with AI design firm Cradle on antibodies | Not in headline | Size unknown |
AI & Pharma section: 506 items collected, 2 selected
One company brought its machine learning unit inside the parent. It also marked down the value of those assets. That was not fresh money. It was a lower estimate of a past bet. The other company chose to design therapeutic proteins with an outside specialist. No figure was given, so the scale is unclear.
A markdown like this admits, on the books, that something is worth less than hoped. The reports do not yet explain the details. In my view, it is too early to call it a failure.
I do not think this sum alone puts the company at risk. Still, it shows how heavy it is to own everything yourself.
For people planning projects in research, this adds a question. Do you keep the capability inside, or rent it? Keep it, and its value is questioned constantly. Partner, and you depend on someone else's situation. Either way, plan your exit before you start.
So for teams that decide to work with an outside partner, what should they check before the rollout begins?
06On the Pharma Front Line
Source IT Brief Australia ／ The Futurum Group ／ tech-insider.org
Even after you decide to bring these tools into the work, checks remain. They cover money, the authority to decide, and other people's rights.
Inference costs balloon
Reports said autonomous agents could turn small pilot deployments into far larger inference bills.
Who approves tools
During preview, the Microsoft Copilot harness keeps the approval policy for built-in tools on Microsoft's side.
AI and copyright opinion
An EU Advocate General said Gemini faces copyright risk if a chatbot bypasses paywalls or replaces news articles. Not binding.
An assistant that acts on its own may compute many times behind one request. So a bill that looked small in a trial can swell once you scale up. Sometimes the vendor holds the call on what may be used. And in Europe, a view emerged that saving readers the trip to the newspaper can raise legal problems.
Why does decision authority matter? In pharma, you must later show who signed off on what. If that record lives only in another firm's settings, you cannot meet your duty to explain.
The European view is only advice to the judges, not a decision. It still hints at where the court may lean, so users should read it.
Pharma documents often draw on papers and press reports. Using machine-written text directly in materials may touch the original authors' rights. Money, authority and rights are all hard to fix after launch. Write them into the plan before the trial.
Apart from money, authority and rights, some figures rarely make the front page. Let us look at them last.
07What Is Being Overlooked
Source Reuters ／ The Globe and Mail ／ Forbes
Big contract announcements usually arrive as good news. Behind them, though, costs and limits can pile up quietly.
| Subject | Reported figure | Source |
|---|---|---|
| AMD chip deals with OpenAI and Meta | $1B cost in a quarter | Reuters |
| Marvell shares | Down 46% since 'next $1 trillion company' call | The Globe and Mail |
| Nvidia's cloud partners | Asked for 51% of sales outside China | Forbes |
One chipmaker booked a large cost on major contracts with model developers. Another chip company, once hyped, has seen its stock fall by about half. The biggest chipmaker asked partners to sell more beyond one particular country. Conditions are appearing on sales promises, on high hopes, and on where products can go. Each shows that the boom comes with strings.
Why do these stories rarely lead the news? The size of the deal takes center stage, and costs and conditions come later. Readers have to go looking for them.
When drug companies plan these projects, they assume today's prices and today's supply. But behind those prices sit the makers' burdens and lines drawn between nations. If those assumptions move, project costs move too. Do not plan on hype alone. Review how billing works and the makers' situation at least once a year.
Who pays for all this in the end? Today's question is now moving toward an answer.
After the vote, will data center plans stall? Watch how rejected projects are handled and how Big Tech reviews capex.
Open the full transcript
Intro
For years, the story of artificial intelligence has been about how smart the machines can get. Today's news raises a different question. Who pays the bill for all that intelligence in the end?
The giant facilities behind it ask a lot of the towns they land in. The money to build them is borrowed on the credit of even bigger companies. And the firms using these tools have started to worry about their invoices. If you are expanding these tools in pharma, this is not distant politics. What happens to your plans if endless growth is no longer safe to assume?
Today we look through money and trust, not performance.
CH 01 The Election and Data Centers
Our first scene is a polling place far away. Did local residents really want these huge computing sites in their own towns?In many towns, the answer was no. Local resistance reportedly shaped the outcome itself. Analysts who track the sector expect large firms to ease back. Money from the boosters did not buy support at the ballot box. So residents now have a say in how far the technology spreads. A force from outside the industry has begun to steer it.Why did residents say no?
The reports do not explain in detail. But these sites draw huge amounts of power. Through power bills and land use, they touch daily life directly. In my reading, that is why opposition comes easily. From the town's view, the burden showed up before any benefit.Drug companies also rely on outside facilities for their computing. If construction slows, renting capacity may cost more. It might not be there when you need it. Plans built on cheap computing lasting forever may need a second look. Still, where do the builders find the money for all this?
Next, we look behind the financing of these sites.
CH 02 Funding the Data Centers
A facility this large costs more than one company can carry alone. So what do the lenders rely on when they hand over the money?One firm builds and owns the site, and a model developer uses it. The developer promises to rent it for years. A much bigger company promised to cover part of those payments. That lets lenders assume the big company will pay in the end. So these sites stand on the credit of a tech giant.Why go that far?
The backer has long been an investor in this developer. If the developer cannot secure computing capacity, that stake suffers too. In my reading, supporting the developer also protects the backer's own money.For a single site, that guarantee looks enormous to me. And one broken promise could hit everyone in the chain, from the lenders to the owner.This matters when a drug company picks a vendor. Prices, and how long a service lasts, depend on how its maker raises money. Checking who stands behind a supplier is ordinary due diligence, I think. After the money, we turn to the people using these tools. How did one provider respond to users who did not want them at all?
CH 03 Schools Saying No to AI, and Search
Users should get to choose whether they use these tools. That sounds obvious. In practice, it is not always true.One major provider decided to keep its tools for children switched off until each school says yes. At first glance, that hands the choice to the school. But saying no also takes away ordinary web lookups. To get them back, the school must accept machine-written digests too. The freedom to refuse exists only on paper. I see this as a vendor's design making the user's decision.Why did it come to this?
Worry is growing among parents and local education leaders. The provider answered by keeping the assistant and lookups tied together. Politicians have pushed back as well, and the company is busy explaining itself.The same thing can happen at a drug company. An everyday work tool may get an assistant built in after the fact. If switching it off stops the whole tool, the vendor really holds the decision. It pays to spot a choice that only looks like one. This fight over control is not limited to children. It has also begun where software engineers do their daily work.
CH 04 OpenAI Takes On GitHub
Will the race in coding assistants be won on intelligence alone?Today's moves suggest a different answer.One lab bought a small firm with technology for keeping code. The target is the place where programmers park their work every day. Hold that, and the assistant can handle everything from writing code to keeping it, in my reading. Another giant added assistants that never stop running. The contest seems to be shifting from raw performance to where the work lives.Why does that place matter?
Programmers gather where their code lives. Once they are used to the tools there, they rarely move. For a vendor, that place keeps customers for years. The more convenient it gets, the harder it is to leave.Drug companies keep internal documents and analysis programs somewhere too. Choosing a tool also means choosing who holds that material. Moving it later takes real effort. So when you pick a home for it, check the exit terms as well. So where are drug companies themselves trying to place these capabilities?
The day's news offers a clue.
CH 05 Pharma's AI Investments
A drug company putting money into this field must choose. Build the capability inside, or borrow it from outside?On this day, both paths surfaced.One company brought its machine learning unit inside the parent. It also marked down the value of those assets. That was not fresh money. It was a lower estimate of a past bet. The other company chose to design therapeutic proteins with an outside specialist. No figure was given, so the scale is unclear.A markdown like this admits, on the books, that something is worth less than hoped. The reports do not yet explain the details. In my view, it is too early to call it a failure.I do not think this sum alone puts the company at risk. Still, it shows how heavy it is to own everything yourself.For people planning projects in research, this adds a question. Do you keep the capability inside, or rent it?
Keep it, and its value is questioned constantly. Partner, and you depend on someone else's situation. Either way, plan your exit before you start. So for teams that decide to work with an outside partner, what should they check before the rollout begins?
CH 06 On the Pharma Front Line
Even after you decide to bring these tools into the work, checks remain. They cover money, the authority to decide, and other people's rights.An assistant that acts on its own may compute many times behind one request. So a bill that looked small in a trial can swell once you scale up. Sometimes the vendor holds the call on what may be used. And in Europe, a view emerged that saving readers the trip to the newspaper can raise legal problems.Why does decision authority matter?
In pharma, you must later show who signed off on what. If that record lives only in another firm's settings, you cannot meet your duty to explain.The European view is only advice to the judges, not a decision. It still hints at where the court may lean, so users should read it.Pharma documents often draw on papers and press reports. Using machine-written text directly in materials may touch the original authors' rights. Money, authority and rights are all hard to fix after launch. Write them into the plan before the trial. Apart from money, authority and rights, some figures rarely make the front page. Let us look at them last.
CH 07 What Is Being Overlooked
Big contract announcements usually arrive as good news. Behind them, though, costs and limits can pile up quietly.One chipmaker booked a large cost on major contracts with model developers. Another chip company, once hyped, has seen its stock fall by about half. The biggest chipmaker asked partners to sell more beyond one particular country. Conditions are appearing on sales promises, on high hopes, and on where products can go. Each shows that the boom comes with strings.Why do these stories rarely lead the news?
The size of the deal takes center stage, and costs and conditions come later. Readers have to go looking for them.When drug companies plan these projects, they assume today's prices and today's supply. But behind those prices sit the makers' burdens and lines drawn between nations. If those assumptions move, project costs move too. Do not plan on hype alone. Review how billing works and the makers' situation at least once a year. Who pays for all this in the end?
Today's question is now moving toward an answer.
Wrap-up
The spread of these tools has not stopped. What is becoming clear is who pays for it. Residents who host the sites, giants who lend their credit, and buyers forced to rethink what they own. If you are expanding them in pharma, do not assume computing stays cheap and endlessly available. What happens to the turned-down projects should be the next clue.
- CH 01Time Magazine「The Winners and Losers of AI's First Big Election」 time.com
- CH 01404 Media「American Voters Overwhelmingly Reject AI Data Centers」 404media.co
- CH 01Bloomberg.com「AI Data Center Boom Set for Upheaval After US Election Rout」 bloomberg.com
- CH 01Benzinga「Democratic Party 2026 Midterm Win Will Hurt ‘Pace of the AI Revolution’: Dan Ives on ‘Blue Tidal Wave’」 benzinga.com
- CH 02Unite.AI「TeraWulf Lines Up Google Backstop for Anthropic’s Kentucky AI Campus」 unite.ai
- CH 03https://tech-insider.org/「Google Turns Off Student Search and Gemini by Default」 tech-insider.org
- CH 03CNBC「Google responds to political backlash over removing search from schools that ban AI」 cnbc.com
- CH 03The Japan Times「Google lets schools turn off Gemini, but not the AI in search」 japantimes.co.jp
- CH 04OpenAI「OpenAI to acquire Pierre Computer Company, Inc.」 openai.com
- CH 04Axios「Exclusive: OpenAI targets Microsoft's GitHub with deal for startup」 axios.com
- CH 04Microsoft「Agents that are persistent | New in Copilot Studio, October 2026 | Microsoft Copilot Blog」 microsoft.com
- CH 05FourWeekMBA「BioNTech to Fold InstaDeep In, Discloses a €96M AI Write-Off」 fourweekmba.com
- CH 05Idéal Investisseur「UCB partners with Cradle to design its antibodies with artificial intelligence」 ideal-investisseur.fr
- CH 06IT Brief Australia「AI agents will multiply your inference bill. Is your enterprise ready?」 itbrief.com.au
- CH 06The Futurum Group「Microsoft Copilot Harness Preview Keeps Tool Approval Policy With Microsoft」 futurumgroup.com
- CH 06tech-insider.org「Google Gemini Copyright Warning: Case C-250/25 [2026]」 tech-insider.org
- CH 07Reuters「AMD's OpenAI, Meta chip deals trigger $1 billion quarterly charge」 reuters.com
- CH 07The Globe and Mail「Marvell Stock Has Plunged 46% Since Jensen Huang Called It the Next $1 Trillion Company. Here's Why.」 theglobeandmail.com
- CH 07Forbes「Nvidia Tells Cloud Partners To Sell 51% Of Services Outside China」 forbes.com
Articles used
- AI Daily News 2026-11-05
- AI and the Pharmaceutical Industry 2026-11-05
- AI Daily News headline translations 2026-11-05 morning
- AI Daily News headline translations 2026-11-04 evening
Today's related reports
- AI Daily News November 5, 2026
- AI & Economy News November 5, 2026
- AI & Finance News November 5, 2026
The narration is synthetic speech. The content draws only on this site's articles from the same day. Each edition passes seven plain-language checks before publication. That means known obstacles to comprehension are held below threshold — it is not a guarantee of comprehension.